Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives
Cholangiocarcinoma is a highly heterogeneous malignant tumor, including intrahepatic cholangiocarcinoma, hepatoportal cholangiocarcinoma and distal cholangiocarcinoma. Its incidence is increasing worldwide and currently accounts for approximately 15% of all primary liver cancers and 3% of all gastro...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2025.1616064/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849709425462345728 |
|---|---|
| author | Yi Wang Yike Li Zhong Liang Yuqiao Zhang Tong Li Chenjun Tian Jinyu Zhao Boru Jin Jie Cao Yanyan Lin Yanyan Lin |
| author_facet | Yi Wang Yike Li Zhong Liang Yuqiao Zhang Tong Li Chenjun Tian Jinyu Zhao Boru Jin Jie Cao Yanyan Lin Yanyan Lin |
| author_sort | Yi Wang |
| collection | DOAJ |
| description | Cholangiocarcinoma is a highly heterogeneous malignant tumor, including intrahepatic cholangiocarcinoma, hepatoportal cholangiocarcinoma and distal cholangiocarcinoma. Its incidence is increasing worldwide and currently accounts for approximately 15% of all primary liver cancers and 3% of all gastrointestinal malignancies. There is a lack of early diagnostic methods for cholangiocarcinoma, and the overall treatment effect is poor, with a 5-year survival rate of less than 25%. New biomarkers are urgently needed in clinical practice to improve the current diagnosis and treatment status. Circulating tumor DNA (ctDNA) is DNA fragments released by tumor cells, which can show tumor-specific gene mutations (such as IDH1/2, FGFR2 fusion) and epigenetic modifications (such as abnormal methylation). With the rapid development of tumor liquid biopsy technology, ctDNA has been gradually applied in solid tumors such as lung cancer and colorectal cancer due to its high sensitivity and dynamic monitoring capabilities. This review systematically introduces ctDNA technology and its progress in early screening, early diagnosis, treatment response, and prognosis monitoring of cholangiocarcinoma. In addition, this review also summarizes the challenges and limitations of current ctDNA technology and analyzes future hot research directions. |
| format | Article |
| id | doaj-art-79cb047924c24efa93404cc0812d33cb |
| institution | DOAJ |
| issn | 2296-634X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj-art-79cb047924c24efa93404cc0812d33cb2025-08-20T03:15:18ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-07-011310.3389/fcell.2025.16160641616064Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectivesYi Wang0Yike Li1Zhong Liang2Yuqiao Zhang3Tong Li4Chenjun Tian5Jinyu Zhao6Boru Jin7Jie Cao8Yanyan Lin9Yanyan Lin10The First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaDepartment of Urology, The First People’s Hospital of Lanzhou City, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaWest China School of Medicine, Sichuan University, Chengdu, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaDepartment of laboratory, The First Hospital of Lanzhou University, Lanzhou, ChinaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, ChinaDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou, ChinaCholangiocarcinoma is a highly heterogeneous malignant tumor, including intrahepatic cholangiocarcinoma, hepatoportal cholangiocarcinoma and distal cholangiocarcinoma. Its incidence is increasing worldwide and currently accounts for approximately 15% of all primary liver cancers and 3% of all gastrointestinal malignancies. There is a lack of early diagnostic methods for cholangiocarcinoma, and the overall treatment effect is poor, with a 5-year survival rate of less than 25%. New biomarkers are urgently needed in clinical practice to improve the current diagnosis and treatment status. Circulating tumor DNA (ctDNA) is DNA fragments released by tumor cells, which can show tumor-specific gene mutations (such as IDH1/2, FGFR2 fusion) and epigenetic modifications (such as abnormal methylation). With the rapid development of tumor liquid biopsy technology, ctDNA has been gradually applied in solid tumors such as lung cancer and colorectal cancer due to its high sensitivity and dynamic monitoring capabilities. This review systematically introduces ctDNA technology and its progress in early screening, early diagnosis, treatment response, and prognosis monitoring of cholangiocarcinoma. In addition, this review also summarizes the challenges and limitations of current ctDNA technology and analyzes future hot research directions.https://www.frontiersin.org/articles/10.3389/fcell.2025.1616064/fullcholangiocarcinomacirculating tumor DNAliquid biopsyprognosis monitoringtumor-informed ctDNA |
| spellingShingle | Yi Wang Yike Li Zhong Liang Yuqiao Zhang Tong Li Chenjun Tian Jinyu Zhao Boru Jin Jie Cao Yanyan Lin Yanyan Lin Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives Frontiers in Cell and Developmental Biology cholangiocarcinoma circulating tumor DNA liquid biopsy prognosis monitoring tumor-informed ctDNA |
| title | Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives |
| title_full | Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives |
| title_fullStr | Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives |
| title_full_unstemmed | Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives |
| title_short | Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives |
| title_sort | circulating tumor dna in cholangiocarcinoma current clinical applications and future perspectives |
| topic | cholangiocarcinoma circulating tumor DNA liquid biopsy prognosis monitoring tumor-informed ctDNA |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2025.1616064/full |
| work_keys_str_mv | AT yiwang circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT yikeli circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT zhongliang circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT yuqiaozhang circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT tongli circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT chenjuntian circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT jinyuzhao circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT borujin circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT jiecao circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT yanyanlin circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives AT yanyanlin circulatingtumordnaincholangiocarcinomacurrentclinicalapplicationsandfutureperspectives |